TY - JOUR
T1 - Sixteen-year longitudinal changes in serum prostate-specific antigen levels
T2 - The Olmsted County study
AU - Jacobsen, Steven J.
AU - Jacobson, Debra J.
AU - McGree, Michaela E.
AU - St Sauver, Jennifer L.
AU - Klee, George G.
AU - Girman, Cynthia J.
AU - Lieber, Michael M.
N1 - Funding Information:
Grant Support: This study was supported in part, by grants from the National Institutes of Health ( DK058859 , AG034676 , AR030582 , and RR000585 ) and Merck Research Laboratories .
Funding Information:
Potential Competing Interests: Dr Girman is an employee of and a shareholder in Merck Research Laboratories. Dr Klee has received research grants and royalties for unrelated technologies from Beckman Coulter, Inc . Dr Jacobsen has received research grants from Beckman Coulter, Inc .
PY - 2012/1
Y1 - 2012/1
N2 - Objective: To determine the distribution of longitudinal changes in serum prostate-specific antigen (PSA) levels from a population-based sample of men. Patients and Methods: In this prospective cohort study, a random sample of Olmsted County, Minnesota, men aged 40 to 79 years in 1990 were followed up biennially from January 1, 1990, through August 29, 2007. Serum PSA levels were determined at each examination, and men were censored for follow-up with a diagnosis of prostate cancer or treatment for benign prostatic hyperplasia. The empirical distributions of annual percent change and annual absolute change in serum PSA level were calculated and tabulated, including the median and 75th and 95th percentiles. Results: For men with PSA measurements 2 years apart, the median annual percent change in serum PSA level was 4.83% and the 95th percentile was about 49.76%. The variability in estimated annual change decreased with increasing time between assessments, with a 95th percentile of 21.82% after 8 or more years between assessments. Although the median absolute change per year increased with increasing age, the median percent change per year was fairly consistent across age groups. Conclusion: These data demonstrate that, with shorter intervals between assessments, greater variability should be expected. These distributions should prove helpful to patients and clinicians in interpreting changes in serum PSA levels observed in typical clinical practices.
AB - Objective: To determine the distribution of longitudinal changes in serum prostate-specific antigen (PSA) levels from a population-based sample of men. Patients and Methods: In this prospective cohort study, a random sample of Olmsted County, Minnesota, men aged 40 to 79 years in 1990 were followed up biennially from January 1, 1990, through August 29, 2007. Serum PSA levels were determined at each examination, and men were censored for follow-up with a diagnosis of prostate cancer or treatment for benign prostatic hyperplasia. The empirical distributions of annual percent change and annual absolute change in serum PSA level were calculated and tabulated, including the median and 75th and 95th percentiles. Results: For men with PSA measurements 2 years apart, the median annual percent change in serum PSA level was 4.83% and the 95th percentile was about 49.76%. The variability in estimated annual change decreased with increasing time between assessments, with a 95th percentile of 21.82% after 8 or more years between assessments. Although the median absolute change per year increased with increasing age, the median percent change per year was fairly consistent across age groups. Conclusion: These data demonstrate that, with shorter intervals between assessments, greater variability should be expected. These distributions should prove helpful to patients and clinicians in interpreting changes in serum PSA levels observed in typical clinical practices.
UR - http://www.scopus.com/inward/record.url?scp=84855712723&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855712723&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2011.09.002
DO - 10.1016/j.mayocp.2011.09.002
M3 - Article
C2 - 22212966
AN - SCOPUS:84855712723
SN - 0025-6196
VL - 87
SP - 34
EP - 40
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 1
ER -